Bionomics is a clinical-stage biopharmaceutical company focused on developing novel, first-in-class, ion channel modulators to treat patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need.
Utilizing our deep expertise in ion channel biology and translational medicine, we design best-in-class oral, small molecules to modulate ion channel function, influence neurotransmission and consequently downstream signalling in the brain.
We are currently focused on our proprietary on allosteric modulators. Negative allosteric modulators (“NAMs”) of the α7 receptor are developed for the treatment of anxiety and stressor related disorders. and Positive allosteric modulators (“PAMs”) are developed for the treatment of cognitive dysfunction.
Bionomics’ lead asset BNC210 is currently in late-stage development for the treatment of Social Anxiety Disorder and Post-Traumatic Stress Disorder, for both of which Bionomics received Fast Track Designation from the U.S. Food and Drug Administration